Therapeutic Hypothermia With Propofol in Survival and Neurological Prognoses After Cardiac Arrest

• Status: Unknown status
• Trial end date: 2016-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Therapeutic hypothermia has been proven to significantly improve the survival and neurological prognoses in patients resuscitated from cardiac arrest. Propofol has been reported to exhibit potentials in mitigating ischemia-reperfusion injury via the antioxidative, anti-inflammatory and neuroprotective mechanisms. This study is to investigate the potentials of propofol in further improving the survival and neurological prognoses in this era of therapeutic hypothermia.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Far Eastern Memorial Hospital
• Treatments: Lorazepam; Propofol

Criteria

Inclusion criteria:

1. non-traumatic cardiac arrest

2. no regain of consciousness after return of spontaneous circulation (ROSC)

3. age >=20 years old and <= 90 years old.

Exclusion criteria:

1. age < 20 y/o or > 90 y/o

2. pregnancy

3. traumatic cardiac arrest

4. fail to achieve ROSC

5. conscious recovery after ROSC

6. contraindications for TH, such as massive bleeding, infections, etc

7. terminal diseases

8. conscious disturbance before cardiac arrest

9. fail to obtain informed consent

10. families refuse to undergo clinical trial

11. allergy to propofol or lorazepam.